The BLZF1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated through targeted disruption of the human BLZF1 gene in the A-549 host cell line. This pooled knockout format provides a heterogeneous mixture of cells carrying diverse loss-of-function mutations, minimizing clonal selection bias and offering a robust model for functional studies.
The A-549 cell line originates from a 58-year-old Caucasian male with lung adenocarcinoma and exhibits key characteristics of alveolar type II-like epithelial cells. It is a widely used model for non-small cell lung cancer (NSCLC) research, particularly for investigating proliferation, migration, invasion, and oncogenic signaling pathways, providing a clinically relevant host background for BLZF1 knockout studies.
BLZF1 encodes a basic leucine zipper (bZIP) transcription factor that acts as a nuclear effector downstream of the MAPK/ERK signaling cascade. Ligand-mediated activation of EGFR triggers the RAS-RAF-MEK pathway, leading to phosphorylation and activation of ERK1 (MAPK3) and ERK2 (MAPK1). Active ERK1/2 then phosphorylate BLZF1, promoting its nuclear translocation and transcriptional regulatory activity. BLZF1 likely dimerizes with other bZIP proteins, such as JUN or FOS family members, to modulate genes involved in cell differentiation and proliferation, positioning it at a critical node in ERK-dependent gene expression.
In the A-549 lung adenocarcinoma context, loss of BLZF1 enables precise interrogation of its contribution to oncogenic behaviors driven by the frequently hyperactivated EGF/ERK pathway. Researchers can assess impacts on cell growth, motility, survival, and the balance between differentiation and proliferation, while the polyclonal format ensures representation of average gene-disruption effects, advantageous for phenotypic screening and transcriptomic analyses.
Typical experimental applications include western blotting to confirm BLZF1 knockout and monitor ERK phosphorylation, RT-qPCR for transcript quantification, and functional assays such as MTS or BrdU proliferation, wound healing migration, transwell invasion, and Annexin V apoptosis detection. Combined with RNA-seq and immunofluorescence, these cells enable comprehensive dissection of BLZF1-regulated networks and lung cancer biology. For additional technical information or custom inquiries, please contact Ascent Research.
